Ethnic differences in psychotropic drug response and pharmacokinetics

Ethno-psychopharmacology: Advances in Current Practice

Volumn , Issue , 2008, Pages 38-61

  Lambert, Timothy ^a   Norman, Trevor R ^b  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84857691631     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511544149.005     Document Type: Chapter

References (143)

1. Allen, J. J., Rack, P.H. & Vaddadi, K.S. (1977). Differences in the effects of clomipramine on English and Asian volunteers. Preliminary report on a pilot study. Postgrad. Med. J, 53(4), 79-86.
2. Alving, A. S. et al. (1956). Enzymatic deficiency in primaquine-sensitive erythrocytes. Science, 124, 484-485.
3. Ananth, J. et al. (2005). Atypical antipsychotic drugs, diabetes and ethnicity. Expert Opin. Drug Saf., 4, 1111-1124.
4. Anderson, K. E. et al. (1991). Diet and cimetidine induce comparable changes in theophylline metabolism in normal subjects. Hepatology, 13, 941-946.
5. Awad, A. G. et al. (1995). Patients’ subjective experiences on antipsychotic medications: implications for outcome and quality oflife. Int. Clin. Psychopharmacol., 10(3), 123-132.
6. Ball, S.E. et al. (1999). Population distribution and effects on drug metabolism of a genetic variant in the 5' promoter region of CYP3A4. Clin. Pharmacol. Ther., 66, 288-294.
7. Beedham, C., Miceli, J. J. & Obach, R. S. (2003). Ziprasidone metabolism, aldehyde oxidase, and clinical implications. J. Clin. Psychopharmacol., 23, 229-232.
8. Bertilsson, L. et al. (1994). Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br. J. Clin. Pharmacol, 38, 471-473.
9. Binder, E. B. & Holsboer, F. (2006). Pharmacogenomics and antidepressant drugs. Ann. Med, 38, 82-94.
10. Botts, S., Littrell, R. & de Leon, J. (2004). Variables associated with high olanzapine dosing in a state hospital. J. Clin. Psychiatry, 65, 1138-1143.
11. Caccia, S. (2000). Biotransformation of post-clozapine antipsychotics: pharmacological implications. Clin. Pharmacokinet., 38, 393-414.
12. Carrillo, J. A. et al. (2003). Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine. J. Clin. Psychopharmacol, 23, 119-127.
13. Carulli, L. et al. (2005). Review article: diabetes, genetics and ethnicity. Aliment. Pharmacol. Ther, 22(2), 16-19.
14. Cashman, J. R. et al. (2001). Population distribution of human flavin-containing monooxygenase form 3: gene polymorphisms. DrugMetab. Dispos., 29, 1629-1637.
15. Chan, H. Y. et al. (2007). Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: a randomized trial. J. Clin. Psychiatry, 68, 29-36.
16. Chang, W. H. et al. (1997). Clozapine dosages and plasma drug concentrations. J. Formos. Med. Assoc., 96, 599-605.
17. Chiu, H. et al. (1992). Neuroleptic prescription for Chinese schizophrenics in Hong Kong. Aust. N. Z. J. Psychiatry, 26, 262-264.
18. Collazo, Y. etal. (1996). Neuroleptic dosing in Hispanic and Asian Inpatients with schizophrenia. Mt. Sinai. J. Med., 63, 310-313.
19. Dalen, P. et al. (1998). 10-Hydroxylation of nortriptyline in white persons with 0, 1,2, 3, and 13 functional CYP2D6 genes. Clin. Pharmacol. Ther, 63, 444-452.
20. Daly, A. K. etal. (1996). Nomenclature for human CYP2D6 alleles. Pharmacogenetics, 6,193-201.
21. Daniel, H. I. & Edeki, T. I. (1996). Genetic polymorphism of S-mephenytoin 4'-hydroxylation. Psychopharmacol. Bull., 32, 219-230.
22. de Leon, J. (2003). Glucuronidation enzymes, genes andpsychiatry. Int. J. Neuropsychopharmacol, 6, 57-72.
23. de Leon, J. et al. (2005a). The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J. Clin. Psychiatry, 66, 15-27.
24. de Leon, J., Armstrong, S.C. & Cozza, K. L. (2005b). The dosing of atypical antipsychotics. Psychosomatics, 46, 262-273.
25. de Leon, J. et al. (2007). Weight gain during a double-blind multidosage clozapine study. J. Clin. Psychopharmacol, 27, 22-27.
26. DeVane, C. L. (1994). Pharmacogenetics and drug metabolism of newer antidepressant agents. J. Clin. Psychiatry, 55(38-45) 46-47.
27. Eichelbaum, M., Ingelman-Sundberg, M. & Evans, W. E. (2006). Pharmacogenomics and individualized drug therapy. Annu. Rev. Med, 57, 119-137.
28. Emsley, R. A. et al. (2002). Ethnicity and treatment response in schizophrenia: a comparison of 3 ethnic groups. J. Clin. Psychiatry, 63, 9-14.
29. Evans, W. E. & Johnson, J. A. (2001). Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annu. Rev. Genomics Hum. Genet, 2, 9-39.
30. Evans, W. E. & Relling, M. V. (1999). Pharmacogenomics: translating functional genomics into rational therapeutics. Science, 286, 487-491.
31. Frackiewicz, E. J. et al. (1997). Ethnicity and antipsychotic response. Ann. Pharmacother., 31, 1360-1369.
32. Fuhr, U. (1998). Drug interactions with grapefruit juice. Extent, probable mechanism and clinical relevance. DrugSaf., 18, 251-272.
33. Fukuda, T. et al. (2000). The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population. Eur. J. Clin. Pharmacol, 56, 175-180.
34. Gaviria, M., Gil, A. A. &Javaid J. I. (1986). Nortriptyline kinetics in Hispanic and Anglo subjects. J. Clin. Psychopharmacol, 6, 227-231.
35. Gelernter, J. et al. (1999). Population studies of polymorphisms of the serotonin transporter protein gene. Am. J. Med. Genet, 88, 61-66.
36. Goldstein, J. A. et al. (1997). Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics, 7, 59-64.
37. Gray, G. E. & Pi, E. H. (1998). Ethnicity and medication-induced movement disorders. J. Pract. Psychiatry Behav. Health, 5, 259-264.
38. Grohmann, R. et al. (1989). Adverse effects of clozapine. Psychopharmacology, 99, S101-104.
39. Guengerich, F. P. (1999). Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu. Rev. Pharmacol. Toxicol., 39, 1-17.
40. Hwang, R. et al. (2005). Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations. Psychopharmacology, 181, 179-187.
41. Inoue, K. et al. (1997). Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian populations. Pharmacogenetics, 7, 103-113.
42. Ito, K. et al. (2002). A variable number of tandem repeats in the serotonin transporter gene does not affect the antidepressant response to fluvoxamine. Psychiatry Res, 111, 235-239.
43. Jackson, C. W., Markowitz, J. S. & Brewerton, T. D. (1995). Delirium associated with clozapine and benzodiazepine combinations. Ann. Clin. Psychiatry, 7, 139-141.
44. Jann, M. W. et al. (1989). Haloperidol and reduced haloperidol plasma levels in Chinese vs. non-Chinese psychiatric patients. Psychiatry Res., 30, 45-52.
45. Jann, M. W. et al. (1992). Comparison of haloperidol and reduced haloperidol plasma levels in four different ethnic populations. Prog. Neuropsychopharmacol. Biol. Psychiatry, 16, 193-202.
46. Janssen, B. etal. (2004). Validation of polypharmacy process measures in inpatient schizophrenia care. Schizophr. Bull., 30, 1023-1033.
47. Jeste, D. V. etal. (1996). Relationship of ethnicity and gender to schizophrenia and pharmacology of neuroleptics. Psychopharmacol. Bull., 32, 243-251.
48. Jones, D. S. & Perlis, R. H. (2006). Pharmacogenetics, race, and psychiatry: prospects and challenges. Harv. Rev. Psychiatry, 14, 92-108.
49. Jorde, L. B. & Wooding, S. P. (2004). Genetic variation, classification and ‘race’. Nat. Genet, 36, S28-33.
50. Kaholokula, J. K. et al. (2006). Ethnic-by-gender differences in cigarette smoking among Asian and Pacific Islanders. Nicotine Tob. Res., 8, 275-286.
51. Kalow, W., Tang, B. K. & Endrenyi, L. (1998). Hypothesis: comparisons of inter- and intraindividual variations can substitute for twin studies in drug research. Pharmacogenetics, 8, 283-289.
52. Kelly, D. L. et al. (2006). Clozapine utilization and outcomes by race in a public mental health system: 1994-2000. J. Clin. Psychiatry, 67, 1404-1411.
53. Kim, D. K. et al. (2000). Serotonin transporter gene polymorphism and antidepressant response. Neuroreport, 11, 215-219.
54. Kinirons, M. T. etal. (1996). Triazolam pharmacokinetics and pharmacodynamics in Caucasians and Southern Asians: ethnicity and CYP3A activity. Br. J. Clin. Pharmacol, 41, 69-72.
55. Kirchheiner, J. et al. (2001). CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr. Scand, 104, 173-192.
56. Kishimoto, A. & Hollister, L. (1984). Nortriptyline kinetics in Japanese and Americans. J. Clin. Psychopharmacol, 4, 171-172.
57. Krishna, D. R. & Klotz, U. (1994). Extrahepatic metabolism of drugs in humans. Clin. Pharma- cokinet., 26, 144-160.
58. Kryzhanovskaya, L. A. et al. (2006). A review of treatment-emergent adverse events during olanzapine clinical trials in elderly patients with dementia. J. Clin. Psychiatry, 67, 933-945.
59. Kubo, M. et al. (2005). Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic Aripriprazole. Drug Metab. Pharmacokinet, 20, 55-64.
60. Lambert, T. J. R. & Minas, I. H. (1998). Transcultural psychopharmacology and pharmacotherapy. Australasian Psychiatry, 6, 61-64.
61. Lane, H. Y. et al. (2001). A pilot double-blind, dose-comparison study of risperidone in drug- naive, first-episode schizophrenia. J. Clin. Psychiatry, 62, 994-995.
62. Lawson, W. B. (1996). Clinical issues in the pharmacotherapy of African-Americans. Psychopharmacol. Bull., 32, 275-281.
63. Lee, C. et al. (2006). Treatment with olanzapine, risperidone or typical antipsychotic drugs in Asian patients with schizophrenia. Aust. N. Z. J. Psychiatry, 40, 437-445.
64. Lee, M. S. (2005). The pharmacogenetics of antidepressant treatments for depressive disorders. Drug Dev. Res., 65, 170-178.
65. Lesch, K. P. et al. (1993). Isolation of a cDNA encoding the human brain serotonin transporter. J. Neural Transm. Gen. Sect., 91, 67-72.
66. Lin, J. H. &Lu, A. Y. (2001). Interindividual variability in inhibition and induction of cytochrome P450 enzymes. Annu. Rev. Pharmacol. Toxicol., 41, 535-567.
67. Lin, K. M. & Finder, E. (1983). Neuroleptic dosage for Asians. Am. J. Psychiatry, 140, 490-491.
68. Lin, K. M. &Smith, M. W. (2000). Psychopharmacotherapy in the context of culture and ethnicity. In P. Ruiz, ed., Ethnicity andPsychopharmacology. Washington, DC: American Psychiatric Press, 1-36.
69. Lin, K. M. et al. (1988a). Comparison of alprazolam plasma levels in normal Asian and Caucasian male volunteers. Psychopharmacology, 96, 365-369.
70. Lin, K.M. et al. (1988b). Haloperidol and prolactin concentrations in Asians and Caucasians. J. Clin. Psychopharmacol., 8, 195-201.
71. Lin, K.M. et al. (1989). A longitudinal assessment of haloperidol doses and serum concentrations in Asian and Caucasian schizophrenic patients. Am. J. Psychiatry, 146, 1307-1311.
72. Lin, K.M. et al. (1991). Pharmacokinetic and other related factors affecting psychotropic responses in Asians. Psychopharmacol. Bull., 27, 427-439.
73. Lin, K. M. etal. (1996).The evolving science ofpharmacogenetics: clinical and ethnicperspectives. Psychopharmacol. Bull., 32, 205-217.
74. Lin, K. M., Anderson, D. & Poland, R. E. (1997). Ethnic and cultural considerations in psychopharmacotherapy. In D. Dunner, ed., Current Psychiatric Therapy II. Philadelphia, PA: WB Saunders, 75-81.
75. Lin, K.M., Smith, M.W. & Ortiz, V. (2001). Culture and psychopharmacology. Psychiatr. Clin. North Am., 24, 523-538.
76. Linnet, K. (2002). Glucuronidation of olanzapine by cDNA-expressed human UDP- glucuronosyltransferases and human liver microsomes. Hum. Psychopharmacol, 17, 233-238.
77. Liu, C. Y. etal. (2003). Optimal dose of risperidone and olanzapine for patients with schizophrenia in Taiwan. Int. Clin. Psychopharmacol, 18, 49-51.
78. Lu, M. L. et al. (2000). Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients. J. Clin. Psychiatry, 61, 594-599.
79. Lu, M. L. et al. (2004). Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances. J. Clin. Psychiatry, 65, 766-771.
80. Luo, N. et al. (2004). Drug utilization review of risperidone for outpatients in a tertiary referral hospital in Singapore. Hum. Psychopharmacol, 19, 259-264.
81. Malhotra, A. K., Murphy, G.M. J. & Kennedy, J. L. (2004). Pharmacogenetics of psychotropic drug response. Am. J. Psychiatry, 161, 780-796.
82. Matsuda, K.T. et al. (1996). Clozapine dosage, serum levels, efficacy, and side-effect profiles: a comparison of Korean-American and Caucasian patients. Psychopharmacol. Bull., 32, 253-257.
83. Meyer, U. A. (2000). Pharmacogenetics and adverse drug reactions. Lancet, 356, 1667-1671.
84. Meyer, U. A. et al. (1996). Antidepressants and drug-metabolizing enzymes - expert group report. Acta Psychiatr. Scand., 93, 71-79.
85. Miceli, J. J. et al. (2000). The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers. Br. J. Clin. Pharmacol, 49(1), 65S-70S.
86. Midha, K. K. et al. (1988a). Variation in the single dose pharmacokinetics of fluphenazine in psychiatric patients. Psychopharmacology, 96, 206-211.
87. Midha, K. K. et al. (1988b). A pharmacokinetic study oftrifluoperazine in two ethnic populations. Psychopharmacology, 95, 333-338.
88. Miners, J. O. et al. (2000). Torsemide metabolism by CYP2C9 variants and other human CYP2C subfamily enzymes. Pharmacogenetics, 10, 267-270.
89. Mori, A. etal. (2005).UDP-glucuronosyltransferase 1A4polymorphismsinaJapanesepopulation and kinetics of clozapine glucuronidation. Drug Metab. Dispos., 33, 672-675.
90. Murray, M. (2006). Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents. J. Pharm. Pharmacol., 58, 871-885.
91. Nelson, D. R. (1999). Cytochrome P450 and the individuality of species. Arch. Biochem. Biophys., 369, 1-10.
92. Ng, C. H. (1997). The stigma of mental illness in Asian cultures. Aust. N. Z. J. Psychiatry, 31, 382-390.
93. Ng, C. H. et al. (2004). The emerging role of pharmacogenetics: implications for clinical psychiatry. Aust. N. Z. J. Psychiatry, 38, 483-489.
94. Ng, C. H. et al. (2005). An inter-ethnic comparison study of clozapine dosage, clinical response and plasma levels. Int. Clin. Psychopharmacol, 20, 163-168.
95. Ng, C.H., Norman, T. R., Ho, B. et al. (2006a). A comparison study of sertraline dosages, plasma levels, efficacy and adverse reactions in Chinese versus Caucasian populations. Int. Clin. Psychopharmacol, 21, 87-92.
96. Ng, C. H., Easteal, S., Tan, S. et al. (2006b). Serotonin transporter polymorphisms and clinical response to sertraline across ethnicities. Progress in Neuropsychopharmacology and Biological Psychiatry, 30, 953-957.
97. Olesen, O. V. & Linnet, K. (2001). Contributions of five human cytochrome P450 isoforms to the N-demethylation of clozapine in vitro at low and high concentrations. J. Clin. Pharmacol, 41, 823-832.
98. Paine, M. F. et al. (1997). Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J. Pharmacol. Exp. Ther, 283, 1552-1562.
99. Pi, E. H. (1998). Transcultural psychopharmacology: present and future. Psychiatry Clin. Neu- rosci., 52, S185-187.
100. Pi, E. H. & Gray, G. E. (1998). A cross-cultural perspective on psychopharmacology. Essential Psychopharmacology, 2, 233-259.
101. Pi, E. H., Simpson, G. H. & Cooper, T. B. (1986). Pharmacokinetics of desipramine in Caucasian and Asian volunteers. Am. J. Psychiatry, 143, 1174-1176.
102. Pi, E. H., Tran-Johnson, T. K., Walker, N. R. et al. (1989). Pharmacokinetics of desipramine in Asian and Caucasian volunteers. Psychopharmacol. Bull., 25, 483-487.
103. Pollock, B. G. etal. (2000). Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology, 23, 587-590.
104. Poolsup, N., Li Wan Po, A. & Knight, T. L. (2000). Pharmacogenetics and psychopharmacotherapy. J. Clin. Pharm. Ther., 25, 197-220.
105. Potkin, S.G. et al. (1984). Haloperidol concentrations elevated in Chinese patients. Psychiatry Res., 12, 167-172.
106. Raaska, K., Raitasuo, V., Laitila, J. & Neuvonen, P. J. (2004). Effect of caffeine-containing versus decaffeinated coffee on serum clozapine concentrations in hospitalised patients. Pharmacol. Toxicol., 94, 13-18.
107. Rendic, S. & DiCarlo, F. J. (1997). Human cytochrome P450 enzymes: a status reportsummarizing their reactions, substrates, inducers, and inhibitors. Drug Metab. Rev., 29, 413-580.
108. Rettie, A. E. etal. (1994). Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant ofCYP2C9. Pharmacogenetics, 4, 39-42.
109. Ring, B. J. et al. (1996). Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J. Pharmacol. Exp. Ther., 276, 658-666.
110. Roh, H. K. et al. (1996). Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population. Pharmacogenetics, 6, 441-447.
111. Rudorfer, M. V., Lane, E. A., Chang, W. H., Zhang, M. D. & Potter, W. Z. (1984). Desipramine pharmacokinetics in Chinese and Caucasian volunteers. Br. J. Clin. Pharmacol, 17, 433-440.
112. Ruiz, S. et al. (1996). Neuroleptic dosing in Asian and Hispanic outpatients with schizophrenia. Mt. Sinai J. Med., 63, 306-309.
113. Sata, F. et al. (2000). CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin. Pharmacol. Ther, 67, 48-56.
114. Schwartz, R. S. (2001). Racial profiling in medical research. N. Engl. J. Med, 344, 1392-1393.
115. Segal, S. P., Bola, J. R. & Watson, M. A. (1996). Race, quality of care, and antipsychotic prescribing practices in psychiatric emergency services. Psychiatr. Serv., 47, 282-286.
116. Serretti, A., Lilli, R. & Smeraldi, E. (2002). Pharmacogenetics in affective disorders. Eur. J. Pharmacol., 438, 117-128.
117. Shimada, T. et al. (1994). Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver micro- somes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther, 270, 414-423.
118. Shimoda, K. et al. (2002). The impact of CYP2C19 and CYP2D6 genotypes on metabolism of amitriptyline in Japanese psychiatric patients. J. Clin. Psychopharmacol, 22, 371-378.
119. Sim, K. et al. (2004). Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia. Br. J. Clin. Pharmacol, 58, 178-183.
120. Sinha, M. et al. (2006). Self-reported race and genetic admixture. N. Engl. J. Med., 354, 421-422.
121. Smeraldi, E. et al. (1998). Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol. Psychiatry, 3, 508-511.
122. Sussman, L.K., Robins, L.N. &Earls, F. (1987). Treatment-seeking for depression by black and white Americans. Soc. Sci. Med., 24, 187-196.
123. Swartzman, L. C. & Burkell, J. (1998). Expectations and the placebo effect in clinical drug trials: why we should not turn a blind eye to unblinding, and other cautionary notes. Clin. Pharmacol. Ther, 64, 1-7.
124. Tayeb, M. T. et al. (2000). CYP3A4 promoter variant in Saudi, Ghanaian and Scottish Caucasian populations. Pharmacogenetics, 10, 753-756.
125. Thummel, K. E. etal. (1994). Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. J. Pharmacol. Exp. Ther., 271, 557-566.
126. Todesco, L. etal. (2003). Determination of-3858G->A and-164C->A genetic polymorphisms of CYP1A2 in blood and saliva by rapid allelic discrimination: large difference in the prevalence of the -3858G->A mutation between Caucasians and Asians. Eur. J. Clin. Pharmacol, 59, 343-346.
127. Verma, S. K. et al. (2005). Plasma risperidone levels and clinical response in patients with first- episode psychosis. J. Clin. Psychopharmacol, 25(6), 609-611.
128. Vesell, E. S. (1989). Pharmacogenetic perspectives gained from twin and family studies. Pharmacol. Ther., 41, 535-552.
129. Wandel, C. etal. (2000). CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4* 1B5'-promoter region polymorphism. Clin. Pharmacol. Ther., 68, 82-91.
130. Wang, L. etal. (2007). Response of risperidone treatment may be associated with polymorphisms of HTT gene in Chinese schizophrenia patients. Neurosci. Lett, 414, 1-4.
131. Weiss, U. et al. (2005). Effects of age and sex on olanzapine plasma concentrations. J. Clin. Psychopharmacol, 25, 570-574.
132. Wu, W. N. & McKown, L. A. (2000). Recent advances in biotransformation of CNS and cardiovascular agents. Curr. Drug Metab., 1, 255-270.
133. Xie, H.-G. et al. (2001). Molecular basis of ethnic differences in drug disposition and response. Annu. Rev. Pharmacol. Toxicol, 41, 815-850.
134. Xing, Q. et al. (2006a). The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients. Int. J. Neuropsy- chopharmacol., 10, 631-637.
135. Xing, Q. et al. (2006b). Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients. Pharmacogenomics, 7, 987-993.
136. Yokoi, F. et al. (2002). Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study usingpositron emission tomography and (11C)raclopride. Neuropsychopharmacology, 27, 248-259.
137. Yoshida, K. et al. (2002). Monoamine oxidase: a gene polymorphism, tryptophan hydroxylase gene polymorphism and antidepressant response to fluvoxamine in Japanese patients with major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry, 26, 1279-1283.
138. Yu, Y. W. etal. (2002). Association study ofthe serotonin transporterpromoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol. Psychiatry, 7, 1115-1119.
139. Yue, Q.Y. et al. (1998). Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes. Clin. Pharmacol. Ther, 64, 384-390.
140. Zanardi, R. et al. (2000). Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. J. Clin. Psychopharmacol, 20(1), 105-107.
141. Zanardi, R. etal. (2001). Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biol. Psychiatry, 50,323-330.
142. Zhang-Wong, J. et al. (1998). An investigation of ethnic and gender differences in the pharmacodynamics of haloperidol. Psychiatry Res., 81, 333-339.
143. Zhou, Z. L. et al. (2006). Multiple dose pharmacokinetics of risperidone and 9- hydroxyrisperidone in Chinese female patients with schizophrenia. Acta Pharmacol. Sin., 27, 381-386.